- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
ATL expects flat Q3 revenues
Ultrasound vendor ATL reported lastweek that it is not expecting any improvement in third-quarterrevenues due to ongoing difficult market conditions in the U.S.and Europe. According to preliminary internal estimates conductedby the Bothell, WA-based
Ultrasound vendor ATL reported lastweek that it is not expecting any improvement in third-quarterrevenues due to ongoing difficult market conditions in the U.S.and Europe. According to preliminary internal estimates conductedby the Bothell, WA-based company, third-quarter revenues willprobably be similar to, but will not exceed, those of the secondquarter of this year. ATL reported second-quarter revenue of $84.8million, down 5% compared to the same period a year ago (SCAN8/10/94).
ATL is pinning hopes for a recovery in part on Apogee 800,a mid-range scanner acquired through the vendor's merger withInterspec. ATL is in the midst of a worldwide roll-out of theproduct.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
